Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. AIMD
AIMD logo

AIMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.600
Open
1.480
VWAP
1.53
Vol
25.15K
Mkt Cap
10.68M
Low
1.450
Amount
38.39K
EV/EBITDA(TTM)
--
Total Shares
6.98M
EV
20.21M
EV/OCF(TTM)
--
P/S(TTM)
48.22
Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Show More

Events Timeline

(ET)
2026-03-09
08:50:00
Ainos Plans to Install 200 AI Nose Systems in Semiconductor Front-End by 2026
select
2026-03-02 (ET)
2026-03-02
08:50:00
Ainos Confirms Initial Order of 1,400 AI Nose Systems
select
2026-02-23 (ET)
2026-02-23
08:50:00
Ainos Signs Strategic Framework with ASE to Deploy 20,000 AI Nose Units
select
2026-02-17 (ET)
2026-02-17
08:40:00
Ainos Announces Interim Results of VELDONA Clinical Trial
select
2026-02-09 (ET)
2026-02-09
08:50:00
Ainos Begins AI Nose Deployments with First $2.1 Million Order
select
2026-02-02 (ET)
2026-02-02
08:30:00
Ainos Partners with Mirle Automation to Develop AI Sensing Technology
select
2026-01-07 (ET)
2026-01-07
08:50:00
Ainos Enters Distribution Agreement with Trusval, Initial Purchase Commitment of 600 AI Nose Units
select
2026-01-02 (ET)
2026-01-02
08:40:00
Ainos CEO Outlines Long-Term Strategy to Digitize Smell
select
2025-12-16 (ET)
2025-12-16
08:50:00
Ainos to Relocate U.S. Headquarters to Houston, Texas
select
2025-10-14 (ET)
2025-10-14
08:42:26
Ainos and NEXCOM Collaborate to Enhance AI Nose Ecosystem
select

News

Benzinga
9.5
01-28Benzinga
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
  • Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
  • Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
  • Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
  • Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
NASDAQ.COM
9.5
2025-08-13NASDAQ.COM
Ainos Posts Wider Loss in Fiscal Q2
  • Financial Performance: Ainos reported a net loss of $4.08 million for Q2 2025, with operating expenses rising 24% year-over-year and cash reserves declining by 68.6%, despite generating its first commercial revenue from the AI Nose platform.

  • Strategic Developments: The company is transitioning to early-stage commercial deployment, focusing on expanding its AI Nose technology and advancing VELDONA therapies through clinical trials, while securing partnerships to enhance distribution and production capabilities.

Benzinga
9.5
2025-08-06Benzinga
Nasdaq Surges 1%; Uber Sales Top Estimates
  • U.S. Stock Market Performance: U.S. stocks rose mid-week, with the Nasdaq Composite up 1%, while the Dow and S&P 500 also saw gains. Consumer staples performed well, but health care stocks declined.

  • Company Earnings Highlights: Uber reported strong second-quarter results, exceeding revenue expectations. In contrast, several companies like Fractyl Health and LifeMD faced significant stock drops due to disappointing earnings or guidance.

Benzinga
4.5
2025-08-06Benzinga
US Stocks Edge Higher; McDonald's Posts Upbeat Earnings
  • Market Performance: U.S. stocks saw modest gains with the Nasdaq Composite up 0.2%, while McDonald's reported better-than-expected quarterly earnings, boosting its stock price.

  • Sector Movements: Energy shares rose by 0.8%, whereas utilities fell by 0.8%. In commodities, oil prices increased by 1.7%, while gold and silver experienced slight declines.

TipRanks
2.0
2025-06-29TipRanks
Upcoming Stock Splits This Week (June 30 to July 4) – Stay Invested
  • Upcoming Stock Splits: Several companies, including Ainos, Helius Medical Technologies, APi Group, Channel Therapeutics, and SciSparc, are implementing stock splits or reverse stock splits between June 30 and July 4 to either boost share prices or make stocks more accessible to investors.

  • Purpose of Stock Splits: Stock splits increase the number of shares while maintaining market value, making stocks more affordable, whereas reverse splits reduce share count to meet exchange requirements and avoid delisting.

Yahoo Finance
7.5
2025-03-11Yahoo Finance
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
  • Collaboration Announcement: Ainos, Inc. has partnered with Advanced Semiconductor Engineering (ASE) to integrate its AI-powered scent digitization technology, known as AI Nose, into semiconductor manufacturing, aiming to enhance process efficiency, environmental safety, and compliance with ESG regulations.

  • Technological Advancements: The AI Nose technology will enable real-time monitoring of airborne chemicals, predictive maintenance, and improved manufacturing precision, ultimately contributing to smarter and more sustainable factory operations.

Valuation Metrics

The current forward P/E ratio for Ainos Inc (AIMD.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Ainos Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what’s a good buy for day trading
Intellectia · 2418 candidates
Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AZN logo
AZN
AstraZeneca PLC
298.35B
PLAG logo
PLAG
Planet Green Holdings Corp
30.35M
AQST logo
AQST
Aquestive Therapeutics Inc
509.36M
CATX logo
CATX
Perspective Therapeutics Inc
351.47M
ASTI logo
ASTI
Ascent Solar Technologies Inc
29.36M
PAVM logo
PAVM
PAVmed Inc
9.16M

Whales Holding AIMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Ainos Inc (AIMD) stock price today?

The current price of AIMD is 1.53 USD — it has increased 3.38

What is Ainos Inc (AIMD)'s business?

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

What is the price predicton of AIMD Stock?

Wall Street analysts forecast AIMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Ainos Inc (AIMD)'s revenue for the last quarter?

Ainos Inc revenue for the last quarter amounts to 2.17K USD, decreased

What is Ainos Inc (AIMD)'s earnings per share (EPS) for the last quarter?

Ainos Inc. EPS for the last quarter amounts to -0.64 USD, decreased -60.98

How many employees does Ainos Inc (AIMD). have?

Ainos Inc (AIMD) has 44 emplpoyees as of March 11 2026.

What is Ainos Inc (AIMD) market cap?

Today AIMD has the market capitalization of 10.68M USD.